Clare has more than 22 years’ experience in neuroscience drug discovery across big pharma, biotech and specialist service companies. Clare joined Harness from independent consultancy, where she advised biotech and pharma teams on research strategy, biomarkers and in vitro models for neurodegenerative and neuroinflammatory diseases. Previously, she was CSO of Talisman Therapeutics, a provider of human iPSC-derived disease models, where she built and led the scientific team, while also leading anti-tau antibody discovery as Head of R&D at Gen2 Neuroscience. Before this, Clare held roles of increasing responsibility at MedImmune, Xention, NeuroSolutions and AstraZeneca, leading teams and projects in neuroscience, pain and inflammation. Clare holds a PhD in Molecular Pharmacology from the University of Cambridge